Article: Shire Announces Study Results With Once-Daily Guanfacine Extended Release (GXR) in ADHD Patients Aged 6-17.

Article: Shire Announces NDA Submission of Guanfacine ...
PR Newswire;  August 24, 2006 ;     700+ words ... ... investigational compound guanfacine extended release (previously referred ... The NDA submission of guanfacine extended release is another Shire milestone ... continue development of guanfacine extended release by initiating a Phase ...

Article: Guanfacine extended release may benefit ...
Pediatric News;  February 1, 2008 ;     700+ words ... ... short half-life. The extended release formulation of guanfacine ... assigned to placebo or guanfacine extended release at a dose of 2 mg, 3 mg ... investigators reported that guanfacine extended release was safe and generally ...

Article: Shire Announces Positive Results of Studies With ...
PR Newswire;  May 23, 2007 ;     700+ words ... ... of studies of the investigational medication guanfacine extended release (GXR, previously referred to as SPD503 ... ADHD) in children aged 6 to 17 years. "Guanfacine extended release, the first selective alpha-2A-adrenoceptor ...

Article: Shire Receives Approvable Letter From FDA for INTUNIV(TM) ...
PR Newswire;  June 21, 2007 ;     700+ words ... ... and Drug Administration (FDA) for INTUNIV (guanfacine) extended release tablets (previously referred to as SPD503 ... available ADHD medications." About INTUNIV (guanfacine) Extended Release Tablets Shire is seeking approval of INTUNIV ...

Article: Shire's INTUNIV Guanfacine extended release ...
Biotech Week;  June 3, 2009 ;     700+ words ... ... company, announced new findings on INTUNIV (guanfacine) extended release, a selective alpha-2A-agonist, at a major ... currently being studied as a once-daily, extended release formulation of guanfacine designed to provide ...

Article: Once-Daily INTUNIV guanfacine Extended ...
Pediatrics Week;  November 28, 2009 ;     700+ words ... ... plc , the global specialty biopharmaceutical company, announced the availability of INTUNIV™ (guanfacine) Extended Release Tablets in pharmacies across the United States for the treatment of Attention-Deficit/Hyperactivity Disorder ...

Article: United States : INTUNIV (Guanfacine) Extended ...
TendersInfo;  September 5, 2009 ;     700+ words ... ... has announced that it has received approval from the US Food and Drug Administration (FDA) for INTUNIV (guanfacine) Extended Release Tablets for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents ...